Financing repurposed drugs for rare diseases: a case study of Unravel Biosciences.

Abouarab, Bechara; Bazarian, Christian; Ben Chaouch, Zied; Lo, Andrew W; Mourenza Gonzalez, Guillermo; Novak, Richard; Vigneault, Frederic

Abouarab, Bechara; Bazarian, Christian; Ben Chaouch, Zied; Lo, Andrew W; Mourenza Gonzalez, Guillermo; Novak, Richard; Vigneault, Frederic.

Affiliation

Abouarab B; Sloan School of Management, MIT, Cambridge, USA.
Bazarian C; Laboratory for Financial Engineering, MIT, Cambridge, USA.
Ben Chaouch Z; Sloan School of Management, MIT, Cambridge, USA.
Lo AW; Laboratory for Financial Engineering, MIT, Cambridge, USA.
Mourenza Gonzalez G; Department of Electrical Engineering and Computer Science, MIT, Cambridge, USA.
Novak R; Laboratory for Financial Engineering, MIT, Cambridge, USA.
Vigneault F; Sloan School of Management, MIT, Cambridge, USA. alo-admin@mit.edu.

Orphanet J Rare Dis ; 18(1): 287, 2023 09 12.

Article de En | MEDLINE | ID: mdl-37700316

Sujet(s)
Mots clés

Biotech venture capital; Drug repurposing; Early stage drug development; Rare disease therapeutics

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Commerce / Maladies rares Type d'étude: Health_economic_evaluation / Prognostic_studies Limites: Humans Langue: En Journal: Orphanet J Rare Dis Sujet du journal: MEDICINA Année: 2023 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google